Derma Sciences, Inc. (DSCI) Reports Results From DSC127 Pharmacokinetic Study
6/12/2013 10:15:48 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that all data from the pharmacokinetic (PK) study with 0.03% DSC127 gel has been collected and analyzed. The open-label, single center, Phase 1 PK study enrolled 21 diabetic subjects with at least one chronic non-healing Wagner Grade 1 or 2 plantar neuropathic foot ulcer(s) on the mid and fore foot that was at least 3.0 cm2. Eighteen subjects completed the trial. Three subjects were withdrawn due to adverse events that were deemed unrelated to the investigational drug. Subjects topically applied 0.03% DSC127 to the wound once each day for 28 days. The mean ulcer area at baseline was 9.5 cm2 (Standard Deviation 11.9 cm2).
Help employers find you! Check out all the jobs and post your resume.
comments powered by